A Phase 3 Randomized Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation

Brief description of study

If you have been diagnosed with liver cancer (hepatocellular carcinoma) diagnosed for the first time and have undergone hepatic resection or ablation, you may qualify for this Phase 3 study. The main goal of this study is to test the safety and how effective of an investigational drug called nivolumab (also known as BMS-936558 or OPDIVO®) for patients with liver cancer after hepatic resection or ablation in order to prevent disease recurrence.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.